<?xml version="1.0" encoding="UTF-8"?>
<p id="p0315">Long-term exposure to antiviral drugs leads to the emergence of drug resistance. In addition, in some cases, limitations of standard treatment result from significant renal toxic effects. Therefore, there is a constant need for the development of novel therapeutic agents. Currently, more than 100 active antiviral drug candidates are in advanced preclinical or clinical trials. Most of these clinical-stage drug candidates are being tested for activity against HIV, HBV and HCV.</p>
